Novo Nordisk presented new data suggesting that high-dose Wegovy could facilitate significant weight loss in certain patients, aiming to bolster its competitive standing against rivals like Eli Lilly's Zepbound.
Key Findings from Novo Nordisk Data
At the European Congress on Obesity, Novo Nordisk released an analysis detailing the efficacy of its higher-dose injectable, Wegovy. The data highlights substantial weight reduction in specific patient groups.
- High-Dose Efficacy: Certain patients on the 7.2-milligram dose achieved an average weight loss of 27.7% after 72 weeks in a late-stage clinical trial.
- 'Early Responders': The data specifically points to a group termed "early responders," who lost at least 15% of their body weight within the first 24 weeks (six months of treatment).
- Overall Average: For the high-dose group in the study, the overall average weight loss was nearly 21%.
- Comparison to Previous Doses: Before the 7.2mg dose, the highest available injectable dose (2.4mg) resulted in an average weight loss exceeding 17% at 72 weeks.
Strategic Market Positioning
This new data is strategically important as Novo Nordisk seeks to strengthen its market position against Eli Lilly's Zepbound, which has been recognized for its high efficacy in obesity treatment.
- Novo is positioning the high-dose Wegovy to compete directly with Zepbound, which has demonstrated average weight loss exceeding 20% in late-stage studies.
- The company suggests that the comparable efficacy levels could help Novo regain market share from Lilly.
- Novo has reported that users are increasing their dosage to 7.2mg, and three major U.S. pharmacy benefit managers have added it to their standard formularies as an extension to Wegovy.
Important Caveats and Limitations
Journalists and analysts caution that the reported figures come with significant caveats that users must understand:
- Limited Comparability: It is currently unclear what the average weight loss is for 'early responders' of Zepbound, making direct comparisons difficult.
- No Guarantee: The impressive 28% loss is specific to the 'early responder' group and should not be expected by all users starting high-dose Wegovy.
- Response Rate: In the trial, only about one in four people taking the highest dose exhibited this early response, compared to about one in five on the 2.4mg dose.
- Non-Responders: For patients who did not show an 'early' response, the average weight loss was reported as 15.4%, though experts noted this still represents a "substantial and clinically meaningful weight loss."
